{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T21:07:37Z","timestamp":1777928857539,"version":"3.51.4"},"reference-count":27,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2015,10,14]],"date-time":"2015-10-14T00:00:00Z","timestamp":1444780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Med Screen"],"published-print":{"date-parts":[[2016,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To exploit the prevalence of HPV genotypes 52\/58 in a Chinese population, we evaluated algorithms that the use the Cervista Assay A9 group for primary cervical cancer screening.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The SHENCCAST II trial database was re-analyzed, focussing on the A9 pool of the Cervista HR-HPV Assay. Results for the detection CIN2+ and CIN3+ were correlated with a genotyping assay (MALDI-TOF) and cervical cytology to explore various screening algorithms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This analysis included 8,556 women with a mean age of 38.9. CIN 2+ rates were 2.7% (233\/8556); CIN 3+ rates were 1.7% (141\/8556). Overall HPV infection rates were 11.1% (950\/8556) for Cervista, in which A5\/A6, A7 and A9 groups were 26.5% (227\/950), 22.9% (218\/950) and 67.8% (644\/950), respectively. The HPV A9 group is highly predictive of high-grade cervical lesions (CIN2+ OR\u2009=\u2009103.61, CIN3+ OR\u2009=\u2009128.059). Sensitivity and specificity for Cervista A9 group for CIN 2+ was 85.4% and 94.7%, and for CIN 3+ 89.4% and 93.8% respectively. Cervista A9 Assay followed by triage cytology for non-A9 positives has sensitivity and specificity for CIN2+ of 91.5% of 93.5%, and for CIN 3+ 94.3% and 92.6%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Using the Cervista A9 as the primary screen instead of the full Cervista assay, the percentage referred to colposcopy would decrease from 11.1% to 8.8% and percentage requiring cytology would decrease from 11.1% to 3.6%. Sensitivity of detecting CIN 2+(91.5%), CIN3+(94.3%) would remain similar to the complete Cervista HR-HPV assay for CIN 2+(93.1%), CIN3+(95.0%).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/0969141315604863","type":"journal-article","created":{"date-parts":[[2015,10,14]],"date-time":"2015-10-14T21:58:39Z","timestamp":1444859919000},"page":"38-43","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Evaluation of The Cervista HPV A9 group In Screening Patients for Cervical Cancer"],"prefix":"10.1177","volume":"23","author":[{"given":"Jinghui","family":"Zhao","sequence":"first","affiliation":[{"name":"Peking University Shenzhen Hospital, Shenzhen, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Du","sequence":"additional","affiliation":[{"name":"Peking University Shenzhen Hospital, Shenzhen, PR China"},{"name":"Shenzhen Key Laboratory on Technology for Early Diagnosis of Major Gynecological diseases, Shenzhen, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerome L","family":"Belinson","sequence":"additional","affiliation":[{"name":"Preventive Oncology International, Inc. Cleveland Heights, USA and Cleveland Clinic, Women\u2019s Health Institute, Cleveland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinfeng","family":"Qu","sequence":"additional","affiliation":[{"name":"Preventive Oncology International, Inc. Cleveland Heights, USA and Cleveland Clinic, Women\u2019s Health Institute, Cleveland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Peking University Shenzhen Hospital, Shenzhen, PR China"},{"name":"Shenzhen Key Laboratory on Technology for Early Diagnosis of Major Gynecological diseases, Shenzhen, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Mei","sequence":"additional","affiliation":[{"name":"Peking University Shenzhen Hospital, Shenzhen, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Yang","sequence":"additional","affiliation":[{"name":"Cleveland Clinic, Department of Anatomic Pathology, Cleveland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun","family":"Wang","sequence":"additional","affiliation":[{"name":"Peking University Shenzhen Hospital, Shenzhen, PR China"},{"name":"Shenzhen Key Laboratory on Technology for Early Diagnosis of Major Gynecological diseases, Shenzhen, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijie","family":"Zhang","sequence":"additional","affiliation":[{"name":"Peking University Shenzhen Hospital, Shenzhen, PR China"},{"name":"Shenzhen Key Laboratory on Technology for Early Diagnosis of Major Gynecological diseases, Shenzhen, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruifang","family":"Wu","sequence":"additional","affiliation":[{"name":"Peking University Shenzhen Hospital, Shenzhen, PR China"},{"name":"Shenzhen Key Laboratory on Technology for Early Diagnosis of Major Gynecological diseases, Shenzhen, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2015,10,14]]},"reference":[{"key":"bibr1-0969141315604863","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.05.071"},{"key":"bibr2-0969141315604863","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2012.11.030"},{"key":"bibr3-0969141315604863","author":"Dillner J","journal-title":"BMJ337"},{"key":"bibr4-0969141315604863","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji187"},{"key":"bibr5-0969141315604863","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPTUS5EXAS6DKZ"},{"key":"bibr6-0969141315604863","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012724"},{"key":"bibr7-0969141315604863","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70208-0"},{"key":"bibr8-0969141315604863","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPKA6ATAPBZ6JQ"},{"key":"bibr9-0969141315604863","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2007.092627"},{"key":"bibr10-0969141315604863","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02716-14"},{"key":"bibr11-0969141315604863","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-014-0674-1"},{"key":"bibr12-0969141315604863","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPJDAORUY4EYR6"},{"key":"bibr13-0969141315604863","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.2001.6370"},{"key":"bibr14-0969141315604863","doi-asserted-by":"publisher","DOI":"10.1016\/S1386-6532(09)70010-1"},{"key":"bibr15-0969141315604863","unstructured":"ASCCP. HPV Genotyping Clinical Update. 2009; Available from: http:\/\/www.asccp.org\/pdfs\/consensus\/clinical_update_20090408.pdf."},{"key":"bibr16-0969141315604863","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPWTZDT0Q7DOVI"},{"key":"bibr17-0969141315604863","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F"},{"key":"bibr18-0969141315604863","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21955"},{"key":"bibr19-0969141315604863","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.325.7364.572"},{"key":"bibr20-0969141315604863","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-259"},{"key":"bibr21-0969141315604863","first-page":"72","author":"Severini A","year":"2013","journal-title":"International journal of circumpolar health"},{"key":"bibr22-0969141315604863","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-9-124"},{"issue":"4","key":"bibr23-0969141315604863","first-page":"253","volume":"7","author":"Yang Y","year":"2006","journal-title":"Chin J Clin Obstets Gynecol"},{"key":"bibr24-0969141315604863","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10506"},{"key":"bibr25-0969141315604863","doi-asserted-by":"publisher","DOI":"10.1159\/000195885"},{"issue":"1","key":"bibr26-0969141315604863","first-page":"114","volume":"45","author":"Liang LY","year":"2013","journal-title":"Journal of Peking University (Health Sciences)"},{"key":"bibr27-0969141315604863","doi-asserted-by":"publisher","DOI":"10.1097\/LGT.0b013e31824b9bf9"}],"container-title":["Journal of Medical Screening"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0969141315604863","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0969141315604863","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0969141315604863","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:23:40Z","timestamp":1777677820000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0969141315604863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,14]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["10.1177\/0969141315604863"],"URL":"https:\/\/doi.org\/10.1177\/0969141315604863","relation":{},"ISSN":["0969-1413","1475-5793"],"issn-type":[{"value":"0969-1413","type":"print"},{"value":"1475-5793","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,14]]}}}